Imbruvica vs Xtandi
Side-by-side cost comparison based on Medicare Part D data
Imbruvica
Ibrutinib
Manufactured by Pharmacyclics/Janssen
Xtandi
Enzalutamide
Manufactured by Astellas/Pfizer
Xtandi costs 11% less per claim than Imbruvica ($9,331.00 vs $10,445.00). A generic version of Xtandi is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Imbruvica | Xtandi |
|---|---|---|
| Avg Cost Per Claim | $10,445.00 | $9,331.00 |
| Total Medicare Spending | $5.7B | $4.1B |
| Total Beneficiaries | 48,000 | 46,000 |
| Total Claims | 548,000 | 438,000 |
| Annual Cost/Patient | $119,250.00 | $88,848.00 |
| Year-over-Year Change | -8.7% | +9.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Pharmacyclics/Janssen | Astellas/Pfizer |
| Condition | Cancer | Cancer |
| Generic Name | Ibrutinib | Enzalutamide |
Imbruvica vs Xtandi: What the Data Shows
Imbruvica (Ibrutinib) and Xtandi (Enzalutamide) are both used to treat cancer. Based on Medicare Part D data, Xtandi costs $9,331.00 per claim, which is 11% less than Imbruvica at $10,445.00 per claim.
Medicare spent $5.7B on Imbruvica and $4.1B on Xtandi. In terms of patient reach, Imbruvica serves more beneficiaries (48,000 vs 46,000).
Year-over-year spending changed -8.7% for Imbruvica and +9.4% for Xtandi.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Xtandi is cheaper at $9,331.00 per claim, compared to $10,445.00 for Imbruvica. That makes Xtandi about 11% less expensive per claim based on Medicare Part D data.
Yes, both Imbruvica and Xtandi are used to treat cancer. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ibrutinib and generic Enzalutamide can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $5.7B on Imbruvica covering 48,000 beneficiaries, and $4.1B on Xtandi covering 46,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.